| Bruce Harmon |
Bruce Harmon is a businessperson who founded Alternative Construction Technologies, Inc. and Lakeport Business Services, Inc. and who has been at the head of 5 different companies. Currently, he is Chief Financial Officer for Blue Water Biotech, Inc. Mr. Harmon is also on the board of Dale Biotech LLC and Member of Association of Certified Fraud Examiners and Member of The Financial Executives Networking Group, Inc.
In his past career he was Chairman, Chief Financial & Accounting Officer at eLayaway, Inc., Chief Financial Officer of Green Innovations Ltd. and CEO, CFO, Secretary, Treasurer & Director at Winecom, Inc. (a subsidiary of Green Innovations Ltd.), Director at Alternative Construction Technologies, Inc., Director, Chief Executive & Financial Officer for Omni Ventures, Inc., Chief Financial Officer for SinoFresh HealthCare, Inc., Chief Financial Officer of Organa Technologies Group, Inc., Chief Financial Officer & Director at Green Hygienics, Inc., Chief Financial Officer & Director at VRDT Corp., Chief Financial Officer at Marizyme, Inc., Chief Financial Officer at Tauriga Sciences, Inc., Chief Financial Officer for Rhamnolipid, Inc., Controller for ViroGroup, Inc. and Chief Financial Officer of K2 Digital, Inc.
Bruce Harmon received an undergraduate degree from Missouri State University. |
| James E. Sapirstein |
James E. Sapirstein is a businessperson who founded Tobira Therapeutics, Inc. and who has been at the head of 7 different companies. He occupies the position of Chairman, President & Chief Executive Officer at First Wave Biopharma, Inc. and Executive Chairman at Blue Water Biotech, Inc. He is also Director & Member-Emerging Companies at Biotechnology Innovation Organization and on the board of 5 other companies.
In his past career he held the position of Chairman-Emeritus at BioNJ, Inc., Chairman & Chief Executive Officer of Marizyme, Inc., Chief Executive Officer & Director at Hepion Pharmaceuticals, Inc., Manager-International Operations at Eli Lilly & Co., Director-International Marketing at Bristol Myers Squibb Co., Global Marketing Lead at Gilead Sciences, Inc., President, Chief Executive Officer & Director at Tobira Therapeutics, Inc., Chief Executive Officer & Director at Alliqua BioMedical, Inc., Product Director at Hoffmann-La Roche, Inc. and Executive Vice President-Metabolic & Endocrinology at EMD Serono, Inc.
He received an MBA from Fairleigh Dickinson University and an undergraduate degree from Rutgers State University of New Jersey. |
| Brian Price |
Brian Price is Head-Technology Strategy at Blue Water Vaccines, Inc.
In the past he occupied the position of Vice President-Pharmaceutical Development at Myonexus Therapeutics, Inc.
Dr. Price received a doctorate and an undergraduate degree from The Ohio State University. |
| Jay Newmark |
Currently, Jay Newmark occupies the position of Chief Medical Officer at Blue Water Biotech, Inc. and Chief Medical Officer for Clarus Therapeutics Holdings, Inc.
In the past he held the position of Senior Director-Medical Affairs at OPKO Health, Inc., Chief Medical Officer at Clarus Therapeutics, Inc. and Senior Director-Medical Affairs at Genomic Health, Inc.
He received an MBA from The University of Chicago and a doctorate from the University of Michigan Medical School. |
| Erin Henderson |
Founder of AETOS Group, Inc., Erin Henderson currently is Secretary & Chief Business Officer at Blue Water Biotech, Inc. Mr. Henderson is also on the board of Gainesville Area Chamber of Commerce and Danscompany of Gainesville, Inc.
In his past career he held the position of Managing Partner at AETOS Group, Inc.
Erin Henderson received an undergraduate degree from Auburn University. |
| Neil J. Campbell |
Neil J. Campbell founded SuperNova Diagnostics, Inc. Currently, Dr. Campbell is President, Chief Executive Officer & Director at Blue Water Biotech, Inc. He is also on the board of Life Sciences Pennsylvania.
Dr. Campbell previously held the position of President, Chief Executive Officer & Director at Marizyme, Inc., President, Chief Executive Officer & Director at Helomics Corp. and President & Chief Operating Officer for CASI Pharmaceuticals, Inc.
Dr. Campbell received a doctorate from The University of Liverpool, an MBA and a graduate degree from Webster University (United Kingdom) and an undergraduate degree from Norwich University. |
| Timothy R. Ramdeen |
Timothy R. Ramdeen founded Amplexd Therapeutics LLC. He is President for Sixth Borough Capital Fund LP. He is also on the board of Blue Water Biotech, Inc.
Mr. Ramdeen previously held the position of Chief Investment Officer for Sixth Borough Capital Management LLC.
Timothy R. Ramdeen received an undergraduate degree from Temple University (Pennsylvania) and an MBA from The Leonard N Stern School of Business. |
| Simon Tarsh |
Simon Tarsh is on the board of Blue Water Biotech, Inc. and Senior Managing Director-Finance Enterprise at Deloitte Consulting LP.
Mr. Tarsh received an undergraduate degree from the University of Salford and an MBA from Bayes Business School. |
